HUTCHMED takes savolitinib-osimertinib combo to ESMO 2026

Two positive Phase III NSCLC studies, SAFFRON and SANOVO, will feature as oral presentations at ESMO Congress 2026 in Madrid this October.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
An IV bag hangs from a stand in a medical room with a window to the left and a light-colored armchair and blanket in the background, lit by natural light.

HUTCHMED (China) Limited will present data from more than 25 studies across its oncology pipeline at the European Society for Medical Oncology Congress 2026 in Madrid, with the headline slots going to two Phase III readouts for its savolitinib and osimertinib combination in non-small cell lung cancer.

The dual billing underlines the growing clinical weight of the all-oral, chemotherapy-free regimen, which HUTCHMED is developing alongside AstraZeneca. Both studies were selected as late-breaking abstracts, a designation ESMO reserves for results it considers likely to influence clinical practice.

SAFFRON and SANOVO: what the data showed

The SAFFRON global Phase III study will be presented in the Presidential Symposium on Sunday 25 October, one of the congress's most prominent slots. It evaluated savolitinib combined with osimertinib in patients with EGFR-mutated NSCLC whose disease had progressed on osimertinib and who also carried MET overexpression or amplification. High-level results, reported in August 2026, showed a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival compared with doublet platinum-based chemotherapy. Full hazard ratios, confidence intervals and safety data have not yet been published ahead of the presentation.

The SANOVO China Phase III study addresses a different patient population: previously untreated patients with locally advanced or metastatic NSCLC harbouring activating EGFR mutations and MET overexpression. Its high-level results, also from August 2026, showed a statistically significant PFS improvement and a clinically meaningful OS benefit versus osimertinib monotherapy alone. SANOVO will be presented as a Proffered Paper on Monday 26 October.

Beyond the headline savolitinib data, HUTCHMED is fielding a broad fruquintinib dataset covering colorectal, renal, ovarian, breast, gastric and oesophageal cancers, alongside surufatinib data in neuroendocrine tumours, pancreatic cancer, sarcoma and small cell lung cancer. Fruquintinib, a selective pan-VEGFR inhibitor, is marketed outside mainland China by Takeda under the brand name FRUZAQLA and was approved in the United States and Europe for metastatic colorectal cancer.

Market context and competitive read-across

The EGFR-mutated NSCLC space is one of the most active in oncology. Third-generation EGFR inhibitors such as osimertinib have become standard of care in the first-line setting, but acquired resistance, often driven by MET amplification, remains a central clinical challenge. A savolitinib-osimertinib combination that can delay or overcome that resistance mechanism would address a well-validated, commercially significant unmet need.

AstraZeneca has already pursued this combination under the SAVANNAH and ORCHARD basket programmes, and the SAFFRON readout represents the pivotal confirmation of the approach in the post-progression setting. If the full dataset supports the high-level results, regulatory submissions to the FDA and EMA could follow, potentially positioning savolitinib alongside other MET-directed strategies such as capmatinib and tepotinib, both of which are approved in MET exon 14-skipping NSCLC but face a different patient population.

For HUTCHMED, a strong ESMO showing across both the savolitinib and fruquintinib franchises would reinforce the company's profile as a commercial-stage, multi-asset operator rather than a single-programme biotech. Full datasets from SAFFRON and SANOVO, including subgroup analyses and patient-reported outcomes, will be the primary focus for oncologists and investors attending the congress.

Sector

Topic

Geography